<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    chief executive office of biodesix, scott hutton

    Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022

    Biodesix CEO named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022, recognizing the most accomplished executives in biotech.

    Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021

    Biodesix, Inc. today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15.

    Biodesix Announces Third Quarter 2021 Results and Highlights

    Biodesix, Inc. today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.

    Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer

    Spesana and Biodesix Inc. announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management.

    Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

    Biodesix, Inc. today announced CEO Scott Hutton will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.

    Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting

    Biodesix, Inc. today announced that the company will co-present with Genentech three posters at SITC Nov. 10–14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy.

    Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting

    Biodesix, Inc., a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference.

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc., a data-driven diagnostic solutions company with a focus in lung disease, appoints Dr. Jon Faiz Kayyem to the board of directors.

    Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer

    Biodesix, Inc. announced new interim data published from the large multi-center observational registry study INSIGHT utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify ICI treatment response in patients with advanced NSCLC.


    Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results

    Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment.

    2 3 4 5 6 7 8 9 10